The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: A national population-based study of incident cases between 1989-2009

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 87-98

  Chhay, V ^a   Saxena, S ^b   Cecil, E ^b   Chatu, S ^a   Subramanian, V ^c   Curcin, V ^d   Majeed, A ^b   Pollok, R C ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; MERCAPTOPURINE; STEROID; GLUCOCORTICOID; MESALAZINE; PURINE DERIVATIVE; THIOL DERIVATIVE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; COLON RESECTION; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PREDICTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; ULCERATIVE COLITIS; YOUNG ADULT; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; RISK; TIME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; COLECTOMY; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PURINES; RISK; SULFHYDRYL COMPOUNDS; TIME FACTORS; YOUNG ADULT;

EID: 84915820938     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13017     Document Type: Article

References (48)

1. Timmer A, Mcdonald J, Tsoulis D, Macdonald J. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Sys Rev 2012; 9: CD000478.
2. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management. J Crohns Colitis 2012; 6: 991-1030.
3. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-92.
4. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
5. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53.
6. Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005; 48: 1997-2009.
7. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507-15.
8. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012; 107: 1228-35.
9. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008; 134: 680-7.
10. Ellis MC, Diggs BS, Vetto JT, Herzig DO. Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care. World J Surg 2011; 35: 671-6.
11. Knowles SR, Cook SI, Tribbick D. Relationship between health status, illness perceptions, coping strategies and psychological morbidity: a preliminary study with IBD stoma patients. J Crohns Colitis 2013; 7: e471-8.
12. Johnson P, Richard C, Ravid A, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2004; 47: 1119-26.
13. Suzuki H, Ogawa H, Shibata C, et al. The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis. Dis Colon Rectum 2012; 55: 330-6.
14. Majeed A, Molokhia M. Primary care in the United Kingdom. J Ambul Care Manage 2008; 31: 198-200.
15. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 2004; 21: 5-14.
16. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pr 2010; 60: e128-36.
17. Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211-8.
18. Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology 2004; 126: 665-73.
19. Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1858-66.
20. Ramadas A, Gunesh S, Thomas G, Williams G, Hawthorne A. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
21. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
22. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145: 996-1006.
23. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107: 1879-87.
24. Jen M-H, Saxena S, Bottle A, Aylin P, Pollok RCG. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-31.
25. Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott IDR. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 2013; 38: 935-45.
26. Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Nguyen GC. Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut 2012; 61: 1410-6.
27. Kane S, Cohen R, Aikens J, Hanauer S. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33.
28. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
29. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996; 129: 81-8.
30. Sebastian S, Jenkins H, McCartney S, et al. The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: differing perceptions from a survey of adult and paediatric gastroenterologists. J Crohns Colitis 2012; 6: 830-44.
31. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn' s disease. Inflamm Bowel Dis 2002; 8: 244-50.
32. Louis E, Collard A, Oger A, Degroote E, Aboul Nasr El Yafi F, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-82.
33. Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 23-34.
34. Chatu S, Saxena S, Subramanian V, et al. The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study. Am J Gastroenterol 2014; 109: 409-16.
35. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137: 502-11.
36. Chatu S, Saxena S, Subramanian V, et al. OC-139 Time trends in rates of first surgical resection and thiopurine use in Crohn's disease: retrospective cohort study. Gut 2012; 61(Suppl. 2): A60.
37. Williet N, Pillot C, Abderrahim O, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2012; 18: 1641-6.
38. Sjöberg M, Magnuson A, Björk J, et al. Infliximab as rescue therapy in hospitalised patients with steroidrefractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38: 377-87.
39. Rungoe C, Langholz E, Andersson M. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014; 63: 1607-16.
40. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
41. Chen Y-C, Wu J-C, Haschler I, Majeed A, Chen T-J, Wetter T. Academic impact of a public electronic health database: bibliometric analysis of studies using the general practice research database. PLoS ONE 2011; 6: e21404.
42. NICE Technology Appraisal 140. Infliximab for subacute manifestations of ulcerative colitis, 2011. www.nice.org.uk/guidance/ta140
43. The UK inflammatory bowel disease audit. interim report of the biological therapy audit, 2012. www.rcplondon.ac.uk/sites/default/files/uk-ibd-audit-interim-report-of-the-biological-therapy-audit-19-june-2012-1.pdf
44. Smith M, Blaker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013; 67: 161-9.
45. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
46. Khan N, Abbas AM, Lichtenstein GR, Loftus EV, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013; 145: 1007-15.
47. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
48. Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with infl ammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19: 2098-110.